RPTX (Repare Therapeutics, Inc.) Earnings per share for the last four quarters

Public company logo of Repare Therapeutics, Inc. (RPTX)

Repare Therapeutics (RPTX) revenues are based on payments and royalties from Roche for the development of ATR inhibitors, while the lack of its own profitable products creates a dependency on external financing. The EPS (TTM) price action is currently fixed at 14.80. Repare Therapeutics (RPTX) is implementing a synthetic lethality method, which enables the destruction of dangerous tumors by targeting only damaged DNA segments while preserving the integrity of healthy cells.

RPTX reparerx.com Earnings per share for the last twelve months (02/11/2024 - 02/07/2026)

Repare Therapeutics, Inc. - analytical breakdowns and key metrics (RPTX)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:Repare Therapeutics Inc. (RPTX)
Signature product of Repare Therapeutics Inc.

This indicator is calculated as the percentage change in net earnings per share over the last twelve months relative to the same period last year, measuring the actual efficiency of business capitalization. For Repare Therapeutics (RPTX), which invests in AI screening and CRISPR technologies, the historical year-over-year EPS growth (TTM) reflects the balance between colossal R&D expenditures and the pace of monetizing its technological leadership.

Competitor analysis for Repare Therapeutics

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (immuneering.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months C4 Tx CCCC|Net earnings per share (EPS TTM) BDTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX